Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is a non‑ionic low‑osmolality iodinated contrast medium presented as a 300 mg/ml solution for intravascular use. It enhances the visibility of vascular structures and organs during diagnostic imaging procedures. GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Optiray is an iodinated contrast agent used in radiographic procedures that require enhanced visualization of vascular and tissue structures.

- Computed Tomography (CT) of the head, chest, abdomen and pelvis: Improves delineation of anatomical detail and lesion detection. - Angiography (including cerebral, cardiac and peripheral): Provides high‑contrast opacification of blood vessels for diagnostic assessment. - Intravenous uro‑urography and excretory urography: Enhances visualization of the urinary collecting system. - Myelography: Improves contrast of the spinal canal and nerve roots. - Contrast‑enhanced magnetic resonance imaging (MRI) sequences (off‑label): Occasionally used to augment signal intensity in specific protocols.

Adverse reactions to Optiray are generally related to its iodine‑based composition and route of administration.

Common Side Effects: - Warmth or flushing sensation at the injection site - Nausea or mild vomiting - Transient headache - Mild itching or skin rash - Temporary elevation of serum creatinine - Mild hypotension

Serious or Rare Side Effects: - Severe allergic or anaphylactoid reactions (including bronchospasm and shock) - Acute kidney injury, especially in patients with pre‑existing renal impairment - Cardiac arrhythmias - Pulmonary edema - Seizures - Persistent hypotension requiring intervention

Optiray should be used with careful assessment of patient history and clinical status.

- Renal function assessment: Evaluate baseline creatinine and eGFR before administration. - Allergy history: Screen for prior reactions to iodinated contrast agents or iodine‑containing products. - Thyroid disease: Use caution in patients with hyperthyroidism or thyroid nodules. - Cardiovascular status: Monitor patients with heart failure or unstable hemodynamics. - Concomitant nephrotoxic drugs: Avoid or adjust dosing when used with other renal‑toxic agents. - Store at ambient temperature: Keep in original container, protect from light and moisture.

Optiray may interact with other agents that affect renal function, allergic response, or cardiovascular stability.

Major Interactions (Avoid): - Nephrotoxic antibiotics (e.g., aminoglycosides, vancomycin): Increase risk of acute kidney injury. - High‑dose iodine supplements or thyroid hormone therapy: May exacerbate iodine load and thyroid dysfunction.

Moderate Interactions (Monitor Closely): - Diuretics (especially loop diuretics): Can potentiate volume depletion and renal effects. - Beta‑blockers: May mask early signs of anaphylactoid reactions. - Metformin: Risk of lactic acidosis if renal function declines sharply after contrast exposure. - ACE inhibitors/ARBs: May affect renal perfusion; monitor creatinine levels. - NSAIDs: Additive risk for renal impairment when combined with contrast media.